FimmCyte proudly claims a spot in the prestigious 2024 TOP 100 Swiss Startup Award, ranking #28 overall and achieving 4th place in the biotech sector. Selected by a panel of 100 leading investors...
Results
The FimmCyte Insights
FimmCyte obtains CHF 1 million from the UZH Life Sciences Fund
FimmCyte, a pioneering women's health biotech, announces an investment of 1 million CHF as a convertible loan from the UZH Life Sciences Fund (LSF). FimmCyte’s most advanced program is a...
FimmCyte Recognized in the 2024 TOP 100 Swiss Startup Award
FimmCyte proudly claims a spot in the prestigious 2024 TOP 100 Swiss Startup Award, ranking #28 overall and achieving...
FimmCyte obtains CHF 1 million from the UZH Life Sciences Fund
FimmCyte, a pioneering women's health biotech, announces an investment of 1 million CHF as a convertible loan from the...
FimmCyte welcomes Dr. Markus Kalousek as Chairperson of the Board of Directors
FimmCyte AG, a pioneering women's health biotech, announces the appointment of Dr. Markus Kalousek as chairperson of...